Back to search results

Observational Study for Type 2 Diabetes Mellitus

This study is looking for people with Type 2 Diabetes Mellitus (T2DM) to help researchers understand more about this condition. The main goal is to identify and learn about patients who might be a good fit for future T2DM studies. Researchers also want to see how common certain medications are among people with T2DM in different areas. You could join if you are 18 or older and have T2DM that isn't well-controlled with lifestyle changes alone, or with lifestyle changes and other treatments. This study is observational, meaning it mostly involves collecting information rather than testing a new treatment. Success for this study means gathering important information about patient characteristics and medication use in the T2DM community.

Study design
This is an observational study with a planned enrollment of 2150 participants. It is not testing a specific treatment, but rather collecting information.
What's involved
You would have one visit where your demographics, medical history, and current medications would be recorded. A small blood sample (about 2 mL) would also be collected.
Compensation
Not stated in the trial record.
Follow-up
Information on patient demographics, medical history, and medications will be collected at a single visit.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07606066

A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies

Recruiting
Not specifiedAges 18+Observational
AstraZeneca
~2,150 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:Procedure: assessment

At a glance

Recruiting sites
19 of 76 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patient demographics
Measured over Visit 1 (Single day)
+3 more outcomes measured

Conditions

Type 2 Diabetes

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

76 sites across 45 states
Turkey (Türkiye)7
Hungary6
Florida4
São Paulo4
HU4
Maharashtra4
Brazil3
Karnataka3

Who to contact

AstraZeneca Clinical Study Information Center
[email protected]
1-877-240-9479
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must be ≥ 18 years of age at the time of signing the ICF.
Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World
Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required.
Provision of signed and dated written informed consent (As specified in the Protocol) before any study-specific procedures, sampling, or analysis.

Exclusion

Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol).
Diagnosed with Type 1 diabetes mellitus.
Known pregnancy at the time of visit or having the intention to become pregnant.

What this trial measures

  • Patient demographicsVisit 1 (Single day)

    Summary statistics

  • Medical and surgical historyVisit 1 (Single day)

    Summary statistics

  • Concomitant medicationVisit 1 (Single day)

    Summary statistics

  • HbA1c levelsVisit 1 (Single day)

    Summary statistics